Healthcare utilization and costs for patients initiating Dabigatran or Warfarin

BACKGROUND: Novel oral anticoagulants (NOAC) such as dabigatran, when compared to warfarin, have been shown to potentially reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) together with lower healthcare resource utilization (HCRU) and similar total costs. This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Reynolds, Shannon L., Ghate, Sameer R., Sheer, Richard, Gandhi, Pranav K., Moretz, Chad, Wang, Cheng, Sander, Stephen, Costantino, Mary E., Annavarapu, Srinivas, Andrews, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480105/
https://www.ncbi.nlm.nih.gov/pubmed/28637460
http://dx.doi.org/10.1186/s12955-017-0705-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480105/
https://www.ncbi.nlm.nih.gov/pubmed/28637460
http://dx.doi.org/10.1186/s12955-017-0705-x

Ejemplares similares